ProCE Banner Activity

ExpressPoints
Cancer Conversations™: PARP Inhibitors in Ovarian Cancer

Slideset Download
Download this summary slideset from a live webinar for a quick overview of the evolving use of PARP inhibitors for the management of ovarian cancer.

Released: October 28, 2021

Expiration: October 27, 2022

No longer available for credit.

Share

Faculty

Ursula Matulonis

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Robert E. Coleman

Robert E. Coleman, MD, FRCP

Professor and Honorary Consultant Medical Oncologist
Cancer Clinical Trials Centre
Academic Unit of Clinical Oncology
Weston Park Hospital
Sheffield, England

Kathleen N. Moore

Kathleen N. Moore, MD, MS

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director
Associate Director Clinical Research
Stephenson Cancer Center at OU Health
Oklahoma City, Oklahoma

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Program Director Disclosure

Program Director

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Ursula Matulonis, MD, has disclosed that she has received consulting fees from GlaxoSmithKline, Merck, NextCure, and Novartis.

Faculty Disclosure

Primary Author

Robert E. Coleman, MD, FRCP

Professor and Honorary Consultant Medical Oncologist
Cancer Clinical Trials Centre
Academic Unit of Clinical Oncology
Weston Park Hospital
Sheffield, England

Robert L. Coleman, MD, FACOG, FACS, has disclosed that he has received funds for research support from AbbVie, AstraZeneca, Clovis, Genmab, Immunogen, Merck, and Roche/Genentech; consulting fees from AbbVie, Agenus, Alkermes, Aravive, AstraZeneca, Clovis, Deciphera, Epsilogen, Genmab, Immunogen, Merck, Novocure, and Roche/Genentech; and fees for non-CME/CE services from AstraZeneca.

Kathleen N. Moore, MD, MS

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director
Associate Director Clinical Research
Stephenson Cancer Center at OU Health
Oklahoma City, Oklahoma

Kathleen Moore, MD, has disclosed that she has received consulting fees from Alkernes, Aravive, AstraZeneca, Blueprint, Eisai, Elevar, IMab, Immunogen, Mereo, Merck, Mersana, Myriad, OncoMed, Sorrento, and VBL Therapeutics.